Related references
Note: Only part of the references are listed.Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors
Mauricio T. Tavares et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses
Daniel J. Landsburg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia
Manon Lernoux et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Design, Synthesis, and Pharmacological Evaluation of First-in-Class Multitarget N-Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors
Daniel A. Rodrigues et al.
CHEMMEDCHEM (2020)
Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors, with potent in vitro and in vivo anticancer activity
Chunhui Cheng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors
Ashish Thakur et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 Inhibitors
Regina Martinez et al.
MOLECULES (2020)
Discovery of novel dual c-Met/HDAC inhibitors as a promising strategy for cancer therapy
Hao Hu et al.
BIOORGANIC CHEMISTRY (2020)
Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance
Claudio D'Amore et al.
CELLULAR ONCOLOGY (2020)
Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors
Yuhong Dong et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Structural hybridization as a facile approach to new drug candidates
Halmuthur M. Sampath Kumar et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies
Xuewu Liang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Patient Experiences With Oral Chemotherapy: Adherence, Symptoms, and Quality of Life
Jamie M. Jacobs et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy
Michael F. Emmons et al.
CANCER RESEARCH (2019)
Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases
Kehui Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2
Yu Yu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors
Aixin Geng et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors
Hang Dong et al.
MOLECULES (2019)
Design, Synthesis and Biological Evaluation of Novel Benzoylimidazole Derivatives as Raf and Histone Deacetylases Dual Inhibitors
Xin Chen et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2019)
Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors
Xuewu Liang et al.
FUTURE MEDICINAL CHEMISTRY (2019)
Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy
Yong Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Design, synthesis and evaluate of novel dual FGFR1 and HDAC inhibitors bearing an indazole scaffold
Jian Liu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Zinc binding groups for histone deacetylase inhibitors
Lei Zhang et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2018)
Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment
Songwen Lin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma
Dizhong Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections
Yahui Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously
Jie Zang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of &ITN&IT1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7&ITH&IT-pyrrolo[2,3-&ITd&IT]pyrimidin-2-yl)amino)phenyl)-&ITN&IT8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase 1 (HDAC1) against Malignant Cancer
Yongtao Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer
Heba M. Hesham et al.
MEDICINAL RESEARCH REVIEWS (2018)
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Qinlian Jiao et al.
MOLECULAR CANCER (2018)
Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Kinase inhibitors: the road ahead
Fleur M. Ferguson et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat
Yu-yi Chu-Farseeva et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling
Zhi Huang et al.
THERANOSTICS (2018)
CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
Yasuhiro Oki et al.
HAEMATOLOGICA (2017)
Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat
Lianbin Yao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives
Dong Lu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
Yasuhiro Oki et al.
HAEMATOLOGICA (2017)
Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy
Chao Ding et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action
Julien Masliah-Planchon et al.
ONCOTARGET (2016)
Synthesis and Biological Evaluation of 1-(2-Aminophenyl)-3-arylurea Derivatives as Potential EphA2 and HDAC Dual Inhibitors
Yong Zhu et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2016)
Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC
Fan-Wei Peng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities
Yong Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Design, Synthesis, and Pharmacological Evaluation of Novel N-Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual Inhibitors
Daniel A. Rodrigues et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines
Eugene Guorong Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
Anas Younes et al.
LANCET ONCOLOGY (2016)
Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1H)-pyrazole Derivatives as JAKs Inhibitors
Xuewu Liang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Design, synthesis and biological evaluation of 2-amino-N-(2-aminophenyl)thiazole-5-carboxamide derivatives as novel Bcr-Abl and histone deacetylase dual inhibitors
Xin Chen et al.
RSC ADVANCES (2016)
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors
Sherri Z. Millis et al.
JAMA ONCOLOGY (2016)
Design and synthesis of novel dual-target agents for HDAC1 and CK2 inhibition
M. Purwin et al.
RSC ADVANCES (2016)
Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase
Fan-Wei Peng et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma
Thomas J. Galloway et al.
CLINICAL CANCER RESEARCH (2015)
Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents
Yu Jiao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis
Weiqiang Xing et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold
Jian Liu et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2015)
Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors
Toshio Shimizu et al.
CLINICAL CANCER RESEARCH (2014)
New and emerging HDAC inhibitors for cancer treatment
Alison C. West et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Polypharmacology: Challenges and Opportunities in Drug Discovery
Andrew Anighoro et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Advances in the development of hybrid anticancer drugs
Sebastien Fortin et al.
EXPERT OPINION ON DRUG DISCOVERY (2013)
The Design and Synthesis of a New Class of RTK/HDAC Dual-Targeted Inhibitors
Xuan Zhang et al.
MOLECULES (2013)
Development of a Chimeric c-Src Kinase and HDAC Inhibitor
Kristin S. Ko et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host
Winston Timp et al.
NATURE REVIEWS CANCER (2013)
Development of a Highly Selective c-Src Kinase Inhibitor
Kristoffer R. Brandvold et al.
ACS CHEMICAL BIOLOGY (2012)
Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors
Miao Zuo et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling
Changgeng Qian et al.
CLINICAL CANCER RESEARCH (2012)
Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases
Thomas Beckers et al.
MEDCHEMCOMM (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity
Cheng-Jung Lai et al.
CANCER RESEARCH (2010)
Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer
Xiong Cai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity
Siavosh Mahboobi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Targeting the cancer kinome through polypharmacology
Zachary A. Knight et al.
NATURE REVIEWS CANCER (2010)
Therapeutic Protein Kinase Inhibitors
S. K. Grant
CELLULAR AND MOLECULAR LIFE SCIENCES (2009)
Discovery of Potent and Selective Inhibitors of the Mammalian Target of Rapamycin (mTOR) Kinase
Pawel Nowak et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design
Paul G. Wyatt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Regulation of histone deacetylase 2 by protein kinase CK2
SC Tsai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
